Regular Article CLINICAL TRIALS AND OBSERVATIONS HLA-DRB1*07:01 is associated with a higher risk of asparaginase allergies

نویسندگان

  • Christian A. Fernandez
  • Colton Smith
  • Wenjian Yang
  • Mihir Daté
  • Donald Bashford
  • Eric Larsen
  • W. Paul Bowman
  • Chengcheng Liu
  • Laura B. Ramsey
  • Tamara Chang
  • Victoria Turner
  • Mignon L. Loh
  • Elizabeth A. Raetz
  • Naomi J. Winick
  • Stephen P. Hunger
  • William L. Carroll
  • Suna Onengut-Gumuscu
  • Wei-Min Chen
  • Patrick Concannon
  • Stephen S. Rich
  • Paul Scheet
  • Sima Jeha
  • Ching-Hon Pui
  • William E. Evans
  • Meenakshi Devidas
  • Mary V. Relling
چکیده

HLA-DRB1*07:01 is associated with a higher risk of asparaginase allergies Christian A. Fernandez, Colton Smith, Wenjian Yang, Mihir Daté, Donald Bashford, Eric Larsen, W. Paul Bowman, Chengcheng Liu, Laura B. Ramsey, Tamara Chang, Victoria Turner, Mignon L. Loh, Elizabeth A. Raetz, Naomi J. Winick, Stephen P. Hunger, William L. Carroll, Suna Onengut-Gumuscu, Wei-Min Chen, Patrick Concannon, Stephen S. Rich, Paul Scheet, Sima Jeha, Ching-Hon Pui, William E. Evans, Meenakshi Devidas, and Mary V. Relling

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

CLINICAL TRIALS AND OBSERVATIONS Dexamethasone exposure and asparaginase antibodies affect relapse risk in acute lymphoblastic leukemia

We have previously hypothesized that higher systemic exposure to asparaginase may cause increased exposure to dexamethasone, both critical chemotherapeutic agents for acute lymphoblastic leukemia. Whether interpatient pharmacokinetic differences in dexamethasone contribute to relapse risk has never been studied. The impact of plasma clearance of dexamethasone and anti–asparaginase antibody leve...

متن کامل

CLINICAL OBSERVATIONS, INTERVENTIONS, AND THERAPEUTIC TRIALS A Phase I-II Clinical Trial to Evaluate Removal of CD4 Cells and Partial Depletion of CD8 Cells From Donor Marrow for HLA-Mismatched Unrelated Recipients

We conducted a phase I-II clinical trial to test the hypothesis that removal of CD4 cells from an HLA-mismatched unrelated marrow graft would substantially reduce the risk of grades III-IV graft-versus-host disease (GVHD) and that retention of a specified number of CD8 cells in the graft would be sufficient to prevent rejection. Patients were eligible for this study when an HLA-A, -B, or -DRB1–...

متن کامل

CLINICAL OBSERVATIONS, INTERVENTIONS, AND THERAPEUTIC TRIALS Engraftment and survival after unrelated-donor bone marrow transplantation: a report from the National Marrow Donor Program

We analyzed engraftment of unrelateddonor (URD) bone marrow in 5246 patients who received transplants facilitated by the National Marrow Donor Program between August 1991 and June 1999. Among patients surviving at least 28 days, 4% had primary graft failure (failure to achieve an absolute neutrophil count > 5 3 108/L before death or second stem-cell infusion). Multivariate logistic regression a...

متن کامل

CLINICAL OBSERVATIONS, INTERVENTIONS, AND THERAPEUTIC TRIALS Improved outcome for children with acute lymphoblastic leukemia: results of Dana-Farber Consortium Protocol 91-01

The Dana-Farber Cancer Institute (DFCI) acute lymphoblastic leukemia (ALL) Consortium Protocol 91-01 was designed to improve the outcome of children with newly diagnosed ALL while minimizing toxicity. Compared with prior protocols, post-remission therapy was intensified by substituting dexamethasone for prednisone and prolonging the asparaginase intensification from 20 to 30 weeks. Between 1991...

متن کامل

CLINICAL OBSERVATIONS, INTERVENTIONS, AND THERAPEUTIC TRIALS Unrelated marrow transplantation for adult patients with poor-risk acute lymphoblastic leukemia: strong graft-versus-leukemia effect and risk factors determining outcome

Between 1988 and 1999, 127 patients with poor-risk acute lymphoblastic leukemia (ALL) received a matched unrelated donor transplant using marrow procured by National Marrow Donor Program (NMDP) collection centers and sent out to 46 transplant centers worldwide. Poor risk was defined by the presence of the translocations t(9;22) (n 5 97), or t(4;11) (n 5 25), or t(1;19) (n 5 5). Sixty-four patie...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

عنوان ژورنال:

دوره   شماره 

صفحات  -

تاریخ انتشار 2014